https://www.openbell.ai/ 2026-11-03T17:36:11.447Z hourly 1.0 https://www.openbell.ai/support 2026-11-03T17:36:11.447Z monthly 0.7 https://www.openbell.ai/privacy 2026-11-03T17:36:11.447Z monthly 0.5 https://www.openbell.ai/terms 2026-11-03T17:36:11.447Z monthly 0.5 https://www.openbell.ai/feed.json 2026-11-03T17:36:11.447Z hourly 0.8 https://www.openbell.ai/news/OTL:1793727099000 2026-11-03T17:31:39.000Z daily 0.9 https://cdn.brandfetch.io/OTL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Odfjell Technology Reports Q3 2026 Financial Results Odfjell Technology reported Q3 2026 EBITDA of NOK 241 million, up 90% year over year, with a 17.2% margin. It generated NOK 108 million in free cash flow and reported a 40% trailing cash conversion rate. The company announced it would resume its dividend, while management said it expects stronger market activity in 2027. https://www.openbell.ai/news/COR:1793727095000 2026-11-03T17:31:35.000Z daily 0.9 https://cdn.brandfetch.io/COR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Corticeira Amorim Reports 9M 2026 Financial Results Corticeira Amorim reported a 4.3% decline in sales for the first nine months of 2026, citing lower volumes, an unfavorable product mix, and currency headwinds. Its EBITDA margin remained at 17.5%, while net debt fell to €56.0 million. The Amorim Cork Solutions business unit recorded sales growth and margin expansion. https://www.openbell.ai/news/IWG:1793725345000 2026-11-03T17:02:25.000Z daily 0.9 https://cdn.brandfetch.io/IWG/w/400/h/400?c=1idopYfmtR7ZKg8QMud International Workplace Group plc Reports Q3 2026 Financial Results International Workplace Group plc reported third-quarter 2026 systemwide revenue growth of 12% and group revenue growth of 9%. The company attributed the acceleration to its capital-light expansion strategy and cost-efficiency measures, and raised its full-year 2026 EBITDA expectations to above current market consensus. IWG forecast year-end leverage of 1.4x to 1.5x. https://www.openbell.ai/news/LTMC:1793725318000 2026-11-03T17:01:58.000Z daily 0.9 https://cdn.brandfetch.io/LTMC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lottomatica Group Reports 9M 2026 Financial Results Lottomatica Group reported first-nine-month 2026 revenue of €1.718 billion, up 5% year over year, and adjusted EBITDA of €665 million, up 8%. Its Italian online market share reached a record 32.4% in September, averaging 31.7% in the third quarter. Unfavorable sports betting payouts weighed on Q3 results, but the company reaffirmed its annual guidance. The CIRSA acquisition closing is now expected in the second quarter of 2027. https://www.openbell.ai/news/AL2SI:1793723567000 2026-11-03T16:32:47.000Z daily 0.9 https://cdn.brandfetch.io/AL2SI/w/400/h/400?c=1idopYfmtR7ZKg8QMud 2CRSi Secures Over €60 Million Order from Exaion for AI Servers 2CRSi secured a binding order worth more than €60 million from long-term partner Exaion for 83 NVIDIA HGX B300 AI servers, plus storage and maintenance services. Deliveries are scheduled by the end of 2026, with 17 servers due in early November, 33 by month-end, and the remaining 33 before December ends. The order will support Exaion’s expansion of high-performance computing and AI infrastructure, including private on-premises inference capabilities. https://www.openbell.ai/news/REJL.B:1793723543000 2026-11-03T16:32:23.000Z daily 0.9 https://cdn.brandfetch.io/REJL.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rejlers AB Reports Q3 2026 Financial Results Rejlers AB reported 3.5% year-over-year sales growth in Q3 2026, while EBITA and margins declined. Sweden delivered organic growth, but Finland and Norway faced challenges, with Norway’s EBITA below the prior-year level. Disruptions in the UAE and project delays in Norway also weighed on quarterly performance. https://www.openbell.ai/news/BOOZT:1793723539000 2026-11-03T16:32:19.000Z daily 0.9 https://cdn.brandfetch.io/BOOZT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Boozt AB (publ) Reports Q3 2026 Financial Results Boozt AB reported a 16% year-over-year revenue increase on a constant-currency basis in Q3 2026. Gross margin was 40.0%, and adjusted EBIT margin was 5.5%. After strong trading in October, management raised its full-year outlook, expecting revenue growth and adjusted EBIT margin to reach the high end of previously communicated ranges. https://www.openbell.ai/news/CLR:1793723530000 2026-11-03T16:32:10.000Z daily 0.9 https://cdn.brandfetch.io/CLR/w/400/h/400?c=1idopYfmtR7ZKg8QMud CLERHP Reports H1 2026 Financial Results and Strategic Milestones CLERHP reported consolidated net profit of USD 2.24 million in H1 2026, returning to positive results compared with the same period in 2025. Its balance sheet grew 43% to USD 163.84 million, supported by a USD 308 million increase in the value of its land holdings. The company secured approval for a financing program of up to USD 75 million, rated A- by Moody’s Local Panamá and PCR; total reported financing was USD 69.50 million. Larimar City & Resort remained a key growth driver, with cumulative sales of USD 410.10 million as of October 2026. https://www.openbell.ai/news/NORCO:1793723529000 2026-11-03T16:32:09.000Z daily 0.9 https://cdn.brandfetch.io/NORCO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Norconsult ASA Reports Third Quarter 2026 Financial Results Norconsult ASA reported third-quarter 2026 net revenue of NOK 2,314 million, up 6% year over year, and adjusted EBITA of NOK 242 million. Growth was supported by strong activity in renewable energy and consulting services, while profitability weakened in its Swedish operations. Management expects stable market conditions and continued strength in energy, and is pursuing ongoing measures to improve profitability. https://www.openbell.ai/news/BCHN:1793723508000 2026-11-03T16:31:48.000Z daily 0.9 https://cdn.brandfetch.io/BCHN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Burckhardt Compression Reports H1 2026/27 Earnings and Order Intake Growth Burckhardt Compression reported first-half 2026/27 order intake of CHF 422.5 million, up 5.4% year over year and above analyst expectations, with growth returning in both divisions. Sales declined because of backlog and delivery timing, while the adjusted EBIT margin was 12.8%. Management maintained full-year guidance of CHF 900 million to CHF 1 billion in revenue and an EBIT margin of about 12%, expecting stronger sales in the second half. https://www.openbell.ai/news/CHEMM:1793723506000 2026-11-03T16:31:46.000Z daily 0.9 https://cdn.brandfetch.io/CHEMM/w/400/h/400?c=1idopYfmtR7ZKg8QMud ChemoMetec Upgrades 2026/27 Financial Guidance and Reports Preliminary Q1 Results ChemoMetec raised its 2026/27 guidance, citing stronger-than-expected demand for its instruments, particularly the NC-203, and a lower cost base. It now expects revenue of DKK 570–605 million, up from DKK 560–590 million, and EBITDA of DKK 335–360 million, compared with DKK 330–345 million previously. Preliminary first-quarter revenue was DKK 160.0 million, up 28% year over year, while EBITDA reached DKK 100.3 million, a 63% margin. https://www.openbell.ai/news/MEDCL:1793723503000 2026-11-03T16:31:43.000Z daily 0.9 https://cdn.brandfetch.io/MEDCL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Teva Raises 2026 Sales Forecast for Uzedy Following Strong Q3 Performance Teva raised its 2026 U.S. sales forecast for Uzedy to $290 million–$310 million from $270 million–$290 million, its second increase this year. The schizophrenia treatment generated $85 million in third-quarter 2026 net sales, beating analyst consensus of $74 million. MedinCell receives 5%–10% royalties on sales and may earn up to $105 million in commercial milestone payments; growth has been supported by greater hospital access and more than 800 new monthly prescribers. https://www.openbell.ai/news/TEVA:1793721709000 2026-11-03T16:01:49.000Z daily 0.9 https://cdn.brandfetch.io/TEVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Teva Pharmaceutical Industries Reports Q3 2026 Financial Results and Raises Full-Year Outlook Teva Pharmaceutical Industries reported third-quarter 2026 revenue of $4.395 billion and adjusted EPS of $0.86. Revenue at AUSTEDO, AJOVY and UZEDY rose 21%, 61% and 96% year over year, respectively, offsetting a decline in global generics revenue. Teva raised its full-year outlook to revenue of $16.7 billion–$17.0 billion and adjusted EPS of $1.92–$2.11, and said its biosimilars business is expected to meet its 2027 revenue objective a year early. The company also cited debt refinancings and credit rating upgrades to investment grade; the article did not report a stock-price move.